# Apollo Endosurgery US

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apollo-endosurgery-us

- Industry: Medical Devices & Equipment
- Headquarters: Austin, US
- Website: www.apolloendo.com
- Total disclosed funding: $72M
- Latest round: Series C (Aug 1, 2014)
- Investors on record: 3

## About

Apollo Endosurgery US, Inc. specializes in innovative, minimally invasive weight loss solutions designed to assist individuals in achieving their weight loss goals through advanced medical interventions.Apollo Endosurgery US, Inc. was founded in 2006 in Austin, US, and focuses on developing medical devices and procedures for weight loss. The company has undergone significant growth and has completed 13 deals to date. Its latest funding round, Venture Debt, raised USD 20.00 mn, contributing to a total amount raised of USD 29.00 mn. Chas McKhann currently serves as CEO, while the company's founder is Pankaj Pasricha.Apollo Endosurgery offers Endura Weight Loss Solutions, which encompass innovative, minimally invasive procedures aimed at helping individuals achieve weight loss. Their core offerings include the Endoscopic Sleeve Gastroplasty (ESG), Transoral Outlet Reduction (TORe), and the Orbera™ Intragastric Balloon System. These procedures assist in reducing stomach capacity and enhancing fullness, targeting adult patients with a Body Mass Index (BMI) of 30 to 50 kg/m², particularly across the US, Canada, and other developed markets.The company generates revenue primarily through direct-to-consumer transactions for its medical procedures and device placements. Revenue is realized post-procedure completion, with a structured payment model often involving one-time fees for specific treatments. While exact pricing details are not disclosed, services typically form part of comprehensive weight loss programs that include ongoing medical support, enhancing patient outcomes and satisfaction. Partnerships with healthcare providers further bolster their revenue stream.Apollo Endosurgery US, Inc. is focused on expanding its product offerings and market reach. Future initiatives include the development of new medical devices aimed at enhancing weight loss solutions, with specific timelines for launches yet to be disclosed. The company is also looking to expand geographically into untapped markets, aiming to address obesity in developing regions by 2025. The recent funding from the Venture Debt round will be strategically utilized to support these growth initiatives, following an exit by key investors in 2022.

## Funding rounds

- Series C, Aug 1, 2014, $61M — UT Horizon Fund
- Series A, Oct 8, 2007, $12M — PTV Healthcare Capital, H.I.G. BioHealth Partners

## Investors

- PTV Healthcare Capital (https://capitalatlas.ai/funds/ptv-healthcare-capital) — Series A
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series A
- UT Horizon Fund (https://capitalatlas.ai/funds/ut-horizon-fund) — Series C